Description: LumiraDx is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
Home Page: www.lumiradx.com
LMDX Technical Analysis
3 More London Riverside
London,
SE1 2AQ
United Kingdom
Phone:
44 11 7284 2535
Officers
| Name | Title |
|---|---|
| Mr. Ron Zwanziger | Co-Founder, Chairman & CEO |
| Dr. David Scott Ph.D. | Co-Founder, CTO & Director |
| Dr. Jerome F. McAleer Ph.D. | Co-Founder, Chief Scientist & Director |
| Mr. Dorian LeBlanc CPA | CFO & VP of Global Operations |
| Ms. Veronique Ameye | Exec. VP & Gen. Counsel |
| Ms. Colleen McMillen | VP of Communications |
| Andy Ward | National Sales Director - UK |
| Mr. Peter Scheu | Pres of North American Commercial Operations |
| Mr. David Walton DMS | Chief Commercial Officer |
| Dr. Nigel Lindner | Chief Innovation Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 8.838 |
| Price-to-Book MRQ: | 18.6266 |
| Price-to-Sales TTM: | 0.8814 |
| IPO Date: | 2021-09-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 1513 |